
jan pm et
summari compani make market comprehens line product servic treat
price-to-earnings oper ep
risk assess reflect compani highli
competit industri character technolog
innov new market entrant rang
start-up establish medic product develop
compani must consist enhanc product
develop new one maintain competit stand
howev demand product immun econom
cycl tend exhibit stabl long-term unit price
jan ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
oct pm stock trade
star recommend ew
recent chang buy
strong buy target price
recent chang
highlight section stock
report updat accordingli
invest rationale/risk section
stock report updat shortli
latest news stori ew marketscop
rais target
above-p
ep estim
continu favor view ew leadership
posit structur heart therapi market
expect market rapidli expand upon
present data
trial march expect
posit ew share ew trade
approxim morn news
settlement
ew agre pay million
settl long-stand patent disput
 europ part
settlement compani agre
litig disput relat transcathet
left atrial appendag closur devic
view posit compani
clear air enabl two
medic devic manufactur focu
effort capit rapidli grow
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp ew develop manufactur market product
technolog design treat advanc stage cardiovascular diseas ew categor
product technolog three main area transcathet heart valv therapi thvt surgic heart
valv therapi shvt critic
ew leader transcathet heart valv replac technolog design nonsurg
replac heart valv edward sapien famili valv transcathet aortic heart valv
use treat patient heart valv diseas tradit open-heart surgeri
sub-optimal ew began offer transcathet heart valv patient commerci europ
unit state japan sale ew transcathet heart valv repres
net sale respect
shvt segment core product line carpentier-edward perimount pericardi valv platform
includ valv aortic mitral surgic valv replac ew leader shvt
includ product annuloplasti ring beating-heart mitral repair system ew acquir
harpoon medic inc decemb sale ew surgic tissu heart valv product
repres net sale respect
critic segment make hemodynam monitor system ew world leader
measur patient heart function fluid statu surgic intens care set hemodynam
monitor enabl clinician balanc suppli demand oxygen critic ill patient
play import role enhanc surgic recoveri enabl appropri tissu organ perfus
ultim enabl improv patient outcom surviv sale ew core
hemodynam product repres net sale
competit landscap cardiovascular diseas number one caus death world
top diseas term health care spend nearli everi countri cardiovascular diseas progress
tend worsen time often affect structur individu heart result
compani aim treat cardiovascular diseas highli profit face sever competit
cardiovascular segment medic technolog industri dynam subject signific
chang due cost-of-car consider regulatori reform industri custom consolid
thvt ew primari competitor includ plc boston scientif corpor abbott
laboratori shvt ew primari competitor includ plc
plc critic ew compet primarili varieti compani specif product line includ
inc pulsion medic system se lidco group plc
key maintain grow market share medic devic industri upkeep product
research develop program edward invest sizeabl portion sale effort
 spend million sale compar million
million expect compani continu invest heavili
ew make signific invest improv streamlin establish
transcathet aortic heart valv replac procedur addit ew make signific
invest develop transcathet heart valv technolog design treat mitral
tricuspid valv diseas structur heart condit valvular diseas difficult
treat aortic valv diseas therefor ew could stand benefit significantli pioneer one
first market therapi
financi trend revenu grew billion billion five-year
cumul annual growth rate compound-annual-growth-rate year end decemb adjust ep
compound-annual-growth-rate vs ew typic maintain net cash posit
gener posit free cash flow defin cash flow oper less capit expenditur free
cash flow million vs million compani capit structur posit
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
ew overvalu
neutral sinc januari technic indic ew
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
equip sub-industri next month
posit continu expect
compani sub-industri grow
posit macro environ addit
sub-industri mani product area
histor recession-resist
particularli equip use non-elect
procedur valuat continu high
industri driven expand margin
robust revenu growth compani
industri think lax food
drug administr fda
increas capabl technolog
enabl medic devic manufactur bring
innov product market faster
constant currenc basi expect
revenu sub-industri rise
high-single-digit low-double-digit
percentag driven continu pipelin
innov new product emerg market
expans speed new product
come market increas recent
year success effort
fda reduc approv time medic
devic time see price
pressur incess head wind medic
impact trade war appear mild
far medic equip compani
accord medic devic trade
septemb retaliatori tariff
billion us medic technolog export
although us chines govern
seek lower health care cost provid
equip manufactur insul
industri earlier commentari
medic devic manufactur suggest
impact trade war would manag
provid commentari impact
trade war earn
on-going threat state health
care system current us
administr continu attempt repeal
afford act stop
multipl time gather suffici
number vote pass variou repeal
replac bill recent on-going
lawsuit texa question
constitution
think import watch
mid-term elect novemb
health care appear import topic
hospit spend larg driver medic
equip sale robust
strong us economi
tax cut job act tcja individu
mandat roll think
hospit could see pressur lead
sale pressur medic equip
requir american health
insur without requir
expect lower number american
gener see posit long-term
fundament includ increas global
demand qualiti health care age
popul rise outlay lead
steadi flow innov product
 health equip
sub-index increas vs rise
 composit index year
date septemb
increas composit
base index
five-year market price perform jan
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra maintain buy opinion share edward
lifesci corpor ew maintain target
above-p next ep estim
multipl near middl ew five-year rang ep vs
higher estim rais ep
sale increas million transcathet heart
valv therapi thvt total sale due difficult
comparison prior-year period result stock germani
surgic heart valv therapi shvt declin shvt
primarili relat convers consign inventori model surgic
valv us result increas sale reserv european sale
focal point fell howev sale would grown adjust
germani stock foreign exchang effect despit difficult quarter
sale continu expect robust adopt thvt global /kevin huang
et cfra reiter buy opinion share edward
lifesci corpor ew rais target
above-p ep estim
high-end five-year rang ep vs
ahead view set sale rose
transcathet heart valv therapi double-digit growth
region europ sale aid recoveri franc limit
number procedur last year see robust adopt transcathet
aortic valv replac tavr aid strong intern sale
tavr center /jeffrey loo cfa
analyst research note compani news
pm et cfra lower opinion share buy
strong buy ew rais target
above-p ep estim continu
favor view ew leadership posit structur heart therapi market
expect market rapidli expand upon present data
trial march expect posit ew share
ew trade approxim morn news settlement
ew agre pay million settl
long-stand patent disput europ part
settlement compani agre litig disput relat
transcathet aortic valv certain mitral valv repair devic left
atrial appendag closur devic view posit
compani clear air enabl two medic devic
manufactur focu effort capit rapidli grow
lifesci ew keep target
above-p ep estim multipl
higher end ew five-year rang favor
view ew exposur nascent minimally-invas mitral tricuspid
replac repair market ep vs higher
estim rais ep estim
ep estim sale increas organ
million global transcathet heart valv therapi thvt
busi grew organ ew implement target commerci
introduct centera valv europ remain track obtain
ce mark sapien ultra system ew intend also
control roll-out strategi sapien ultra system encourag
hear ew obtain approv begin pivot trial studi
compani pascal mitral repair system /kevin huang cfa
et cfra add share edward lifesci corpor
top portfolio ew target price
reflect multipl ep estim
peer faster growth within ew five-year rang expect
sale grow billion follow rise
see oper margin expect
continu organ growth rang transcathet
heart valv therapi thvt busi revenu although ew sale
growth moder recent quarter optimist upcom
product launch ew leader grow tavr transcathet aortic
valv replac space continu innov
increas competit tavr market would also note ew
sizeabl cash posit june offer firm greater
financi flexibl mani peer ew replac thermo fisher
scientif top portfolio /cathi seifert
et cfra upgrad opinion share edward lifesci
strong buy buy ew rais target
above-p ep estim
multipl higher end ew five-year rang
ep vs higher estim rais
ep ep
sale increas organ million driven growth
global transcathet heart valv therapi thvt busi
organ thvt revenu growth lower expect declin
market share outsid particularli europ competitor
price aggress think market overreact temporari
slowdown growth long-run think make sens ew maintain
premium price given technolog superior ew
life-sav thvt continu look forward launch sapien
ultra centera valv later year /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim ew earn
usd quarter fiscal year ew
announc earn per share usd repres
total revenu estim fiscal year
analyst estim ew earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
